D. Solit, N. Rosen
Feb 23, 2011
Citations
8
Influential Citations
227
Citations
Quality indicators
Journal
The New England journal of medicine
Abstract
PLX4032, an inhibitor of activated BRAF, has shown clinical efficacy in treating patients with melanomas carrying an activating mutation in BRAF, but resistance to the drug develops in some patients. Two recent studies show possible mechanisms of such resistance.